ATE490240T1 - Mutilinderivate und deren verwendung als antimikrobielle agenzien - Google Patents

Mutilinderivate und deren verwendung als antimikrobielle agenzien

Info

Publication number
ATE490240T1
ATE490240T1 AT05022003T AT05022003T ATE490240T1 AT E490240 T1 ATE490240 T1 AT E490240T1 AT 05022003 T AT05022003 T AT 05022003T AT 05022003 T AT05022003 T AT 05022003T AT E490240 T1 ATE490240 T1 AT E490240T1
Authority
AT
Austria
Prior art keywords
antimicrobial agent
mutilin derivatives
mutilin
derivatives
antimicrobial
Prior art date
Application number
AT05022003T
Other languages
German (de)
English (en)
Inventor
Gerd Ascher
Heinz Berner
Johannes Hildebrandt
Original Assignee
Nabriva Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabriva Therapeutics Ag filed Critical Nabriva Therapeutics Ag
Application granted granted Critical
Publication of ATE490240T1 publication Critical patent/ATE490240T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/76—Ring systems containing bridged rings containing three rings containing at least one ring with more than six ring members
    • C07C2603/80—Ring systems containing bridged rings containing three rings containing at least one ring with more than six ring members containing eight-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05022003T 1999-07-30 2000-07-28 Mutilinderivate und deren verwendung als antimikrobielle agenzien ATE490240T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9918037.4A GB9918037D0 (en) 1999-07-30 1999-07-30 Organic compounds

Publications (1)

Publication Number Publication Date
ATE490240T1 true ATE490240T1 (de) 2010-12-15

Family

ID=10858319

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05022003T ATE490240T1 (de) 1999-07-30 2000-07-28 Mutilinderivate und deren verwendung als antimikrobielle agenzien
AT00956343T ATE319686T1 (de) 1999-07-30 2000-07-28 Mutilin-derivate und ihre anwendung als antibakterielle mittel

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00956343T ATE319686T1 (de) 1999-07-30 2000-07-28 Mutilin-derivate und ihre anwendung als antibakterielle mittel

Country Status (34)

Country Link
US (2) US6784193B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP1198454B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP4711580B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR100878074B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN1182116C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR024964A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (2) ATE490240T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU757799B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (2) BRPI0017527B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2380980C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO5180568A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ2002345A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE60026540T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1198454T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP003591A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2357443T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB9918037D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1047087B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU229483B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL147072A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA02001091A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY133731A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO322562B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ516711A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20010544A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL205609B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1198454E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2276135C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1198454T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK1272002A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR200103764T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI281468B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2001009095A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200200695B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020676A1 (es) 2000-09-13 2002-08-27 Biochemie Gmbh Compuestos de mutilina como antibacterianos
GB0207495D0 (en) 2002-03-28 2002-05-08 Biochemie Gmbh Organic compounds
GB0209262D0 (en) 2002-04-23 2002-06-05 Biochemie Gmbh Organic compounds
BRPI0312882B8 (pt) * 2002-07-24 2021-05-25 Nabriva Therapeutics Ag derivados de pleuromutilina e composição farmacêutica
ES2335284T3 (es) * 2003-09-03 2010-03-24 Glaxo Group Limited Nuevo procedimiento para preparar derivados de pleuromutilina.
GB0504314D0 (en) * 2005-03-02 2005-04-06 Glaxo Group Ltd Novel polymorph
US20080171766A1 (en) * 2005-03-10 2008-07-17 Smithkline Beecham Corporation Novel Method
GB0513058D0 (en) * 2005-06-27 2005-08-03 Sandoz Ag Organic compounds
GB0515995D0 (en) * 2005-08-03 2005-09-07 Sandoz Ag Organic compounds
WO2007037518A1 (ja) * 2005-09-29 2007-04-05 Dainippon Sumitomo Pharma Co., Ltd. ムチリン誘導体及びそれを含有する医薬組成物
EP1808431A1 (en) * 2006-01-16 2007-07-18 Nabriva Therapeutics Forschungs GmbH Mutilin derivatives and their use as pharmaceutical
US8841334B2 (en) * 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
EP2024349B1 (en) * 2006-05-31 2017-08-02 AbbVie Inc. Compounds as cannabinoid receptor ligands and uses thereof
CN102442970A (zh) * 2006-05-31 2012-05-09 雅培制药有限公司 用作大麻素受体配位体的噻唑化合物及其用途
US20070281894A1 (en) * 2006-06-05 2007-12-06 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
EP1908750A1 (en) 2006-10-05 2008-04-09 Nabriva Therapeutics Forschungs GmbH Process for the preparation of pleuromutilins
EP1972618A1 (en) * 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
US7875640B2 (en) 2007-03-28 2011-01-25 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8501794B2 (en) * 2007-04-17 2013-08-06 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7872033B2 (en) * 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8735434B2 (en) * 2007-05-18 2014-05-27 Abbvie Inc. Compounds as cannabinoid receptor ligands
CA2688008A1 (en) 2007-05-24 2008-11-27 Kyorin Pharmaceutical Co., Ltd. Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position
EP2014645A1 (en) * 2007-07-13 2009-01-14 Nabriva Therapeutics AG Pleuromutilin derivatives and their use as antimicrobials
EP2014640A1 (en) * 2007-07-13 2009-01-14 Nabriva Therapeutics AG Pleuromutilin derivatives
US9193713B2 (en) * 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
CA2716857A1 (en) 2008-03-11 2009-09-17 Teodozyi Kolasa Novel compounds as cannabinoid receptor ligands
CN102083797B (zh) 2008-04-01 2014-06-04 Abbvie公司 四氢异喹啉、含有它们的药物组合物和它们在治疗中的用途
US20100035919A1 (en) * 2008-08-05 2010-02-11 Abbott Laboratories Compounds useful as inhibitors of protein kinases
US8173687B2 (en) * 2008-08-15 2012-05-08 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8846730B2 (en) 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
PE20110804A1 (es) 2008-09-16 2011-11-30 Abbott Lab Compuestos novedosos como ligandos de receptores de cannabinoides
PA8845601A1 (es) * 2008-10-17 2010-05-26 Abbott Lab Antagonistas del receptor transitorio potencial de vanilloides 1(trpv1)
US8609692B2 (en) * 2008-10-17 2013-12-17 Abbvie Inc. TRPV1 antagonists
WO2010056855A1 (en) * 2008-11-13 2010-05-20 Teva Pharmaceutical Industries Ltd. Preparation of retapamulin via its pleuromutilin-thiol precursor
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
HUE029289T2 (en) 2008-12-05 2017-02-28 Abbvie Inc Sulfonamide derivatives as Bcl-2 selective apoptosis inducers for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
PA8854001A1 (es) 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
CN104945311A (zh) 2009-01-19 2015-09-30 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
EP2387560A2 (en) * 2009-01-19 2011-11-23 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
TWI519530B (zh) 2009-02-20 2016-02-01 艾伯維德國有限及兩合公司 羰醯胺化合物及其作為鈣蛋白酶（ｃａｌｐａｉｎ）抑制劑之用途
ES2542234T3 (es) * 2009-03-27 2015-08-03 Abbvie Inc. Compuestos como ligandos de receptores cannabinoides
JP2012522004A (ja) 2009-03-27 2012-09-20 アボット・ラボラトリーズ カンナビノイド受容体リガンドである化合物
US8288428B2 (en) * 2009-03-27 2012-10-16 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2243479A3 (en) 2009-04-20 2011-01-19 Abbott Laboratories Novel amide and amidine derivates and uses thereof
US8236798B2 (en) 2009-05-07 2012-08-07 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
EP2435432B3 (en) 2009-05-26 2023-10-25 AbbVie Ireland Unlimited Company Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8962639B2 (en) * 2009-05-29 2015-02-24 Abbvie Inc. Potassium channel modulators
WO2011053740A1 (en) 2009-10-28 2011-05-05 Belkin International, Inc. Portable multi-media communication device protective carrier and method of manufacture therefor
WO2011066168A1 (en) 2009-11-25 2011-06-03 Abbott Laboratories Potassium channel modulators
TW201130855A (en) 2009-12-16 2011-09-16 Abbott Lab Prodrug compounds useful as cannabinoid ligands
WO2011119345A2 (en) 2010-03-25 2011-09-29 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
US8586596B2 (en) 2010-06-15 2013-11-19 Abbvie Inc. Compounds as cannabinoid receptor ligands
AU2010359001A1 (en) 2010-08-10 2013-03-14 Abbvie Inc. Novel TRPV3 modulators
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
CN103119035B (zh) 2010-09-27 2015-09-30 雅培股份有限两合公司 杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途
SG189471A1 (en) 2010-10-29 2013-05-31 Abbvie Inc Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
TW201238950A (en) 2010-11-15 2012-10-01 Abbott Lab NAMPT and rock inhibitors
US20120122924A1 (en) 2010-11-15 2012-05-17 Abbott Laboratories Nampt inhibitors
US8609674B2 (en) 2010-11-16 2013-12-17 Abbvie Inc. Potassium channel modulators
WO2012067822A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators
PL2642999T3 (pl) 2010-11-23 2017-04-28 Abbvie Ireland Unlimited Company Sposoby leczenia z zastosowaniem selektywnych inhibitorów bcl-2
EP2643322B1 (en) 2010-11-23 2017-08-30 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US8802693B1 (en) 2011-03-09 2014-08-12 Abbvie Inc. Azaadamantane derivatives and methods of use
US9012651B2 (en) 2011-03-24 2015-04-21 Abbvie Inc. TRPV3 modulators
US8802711B2 (en) 2011-03-25 2014-08-12 Abbvie Inc. TRPV1 antagonists
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8859549B2 (en) 2011-05-13 2014-10-14 Abbvie, Inc. Potassium channel modulators
TW201319049A (zh) 2011-08-05 2013-05-16 Abbott Gmbh & Co Kg 胺基□唍、胺基硫□唍及胺基－１，２，３，４－四氫喹啉衍生物，包含彼等之醫藥組合物及彼等於治療之用途
TWI561521B (en) 2011-10-14 2016-12-11 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI571466B (zh) 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
JP2014530911A (ja) 2011-10-24 2014-11-20 アッヴィ・インコーポレイテッド Ｔｒｐｖ３モジュレーターとしてのメタノール誘導体
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
US8846741B2 (en) 2011-11-18 2014-09-30 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8859584B2 (en) 2011-12-19 2014-10-14 Abbvie, Inc. TRPV1 antagonists
US8969325B2 (en) 2011-12-19 2015-03-03 Abbvie Inc. TRPV1 antagonists
CN103204787B (zh) * 2012-01-17 2014-10-01 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013149376A1 (en) 2012-04-02 2013-10-10 Abbott Laboratories Chemokine receptor antagonists
EP2838881B1 (en) 2012-04-20 2018-08-08 AbbVie Inc. Isoindolone derivatives
JP2015516435A (ja) 2012-05-11 2015-06-11 アッヴィ・インコーポレイテッド Ｎａｍｐｔ阻害薬
JP2015516437A (ja) 2012-05-11 2015-06-11 アッヴィ・インコーポレイテッド Ｎａｍｐｔ阻害薬として使用されるチアゾールカルボキサミド誘導体
JP2015516436A (ja) 2012-05-11 2015-06-11 アッヴィ・インコーポレイテッド Ｎａｍｐｔ阻害薬
UY34804A (es) 2012-05-11 2013-12-31 Abbvie Inc Inhibidores del nampt
US20130317055A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonist and methods of use
US20130317054A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonist and methods of use
BR112014031068A2 (pt) 2012-06-12 2017-06-27 Abbvie Inc derivados piridinona e piridazinona
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
CN103626693B (zh) * 2012-08-28 2016-09-14 中国科学院上海药物研究所 一类截短侧耳素衍生物、其药物组合物及其合成方法与用途
US20140080813A1 (en) 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
BR112015005743A2 (pt) 2012-09-14 2017-07-04 Abbvie Deutschland derivados tricíclicos de quinoxalina e quinolina
JP2016512559A (ja) 2013-03-13 2016-04-28 アッヴィ・インコーポレイテッド Ｃｄｋ９キナーゼ阻害薬
AU2014244183A1 (en) 2013-03-13 2015-08-13 Abbvie Inc. Pyridine CDK9 kinase inhibitors
BR112015023187A2 (pt) 2013-03-14 2017-07-18 Abbvie Inc inibidores de pirrolo[2,3 - b] piridina cdk9 kinase
WO2014140184A1 (en) 2013-03-14 2014-09-18 AbbVie Deutschland GmbH & Co. KG Novel inhibitor compounds of phosphodiesterase type 10a
CA2903538A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Pyrrolopyrimindine cdk9 kinase inhibitors
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2970229B1 (en) 2013-03-14 2017-02-08 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases
WO2014151444A1 (en) 2013-03-14 2014-09-25 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2924689A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
AU2014336154A1 (en) 2013-10-17 2016-04-28 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015091931A1 (en) 2013-12-20 2015-06-25 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases
US9328112B2 (en) 2014-02-06 2016-05-03 Abbvie Inc. Tetracyclic CDK9 kinase inhibitors
WO2015173392A1 (en) 2014-05-15 2015-11-19 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a co-bound spiro substituent and use thereof for treating vasopressin-related diseases
US9617226B2 (en) 2014-09-05 2017-04-11 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2016160938A1 (en) 2015-04-02 2016-10-06 Abbvie Inc. N-(1,3-thiazol-2-yl)pyrimidine-5-carboxamides as trpv3 modulators
EP3636651A1 (en) 2015-11-25 2020-04-15 AbbVie Deutschland GmbH & Co. KG Hexahydropyrazinobenz- or -pyrido-oxazepines carrying an oxygen-containing substituent and use thereof in the treatment of 5-ht2c-dependent disorders
DK3452484T3 (da) 2016-05-07 2023-09-25 Fochon Pharmaceuticals Ltd Visse protein-kinase-inhibitorer
CN106565564A (zh) * 2016-09-30 2017-04-19 华南农业大学 一种具有2‑氨基苯巯醇侧链的截短侧耳素衍生物及其制备方法和用途
WO2018058534A1 (zh) * 2016-09-30 2018-04-05 华南农业大学 一种具有2-氨基苯巯醇侧链的截短侧耳素衍生物及其制备方法和用途
US11168078B2 (en) 2016-11-28 2021-11-09 Shanghai Fochon Pharmaceutical Co., Ltd. Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase
TWI762573B (zh) 2017-02-10 2022-05-01 奧地利商納畢瓦治療有限責任公司 截短側耳素之純化
WO2018175449A1 (en) 2017-03-21 2018-09-27 AbbVie Deutschland GmbH & Co. KG Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical
DK3612531T3 (da) 2017-04-18 2022-09-05 Shanghai Fochon Pharmaceutical Co Ltd Apoptose-inducerende midler
CN107417586A (zh) * 2017-06-21 2017-12-01 华南农业大学 一种截短侧耳素类抗生素及其制备方法和应用
CN109384698B (zh) * 2017-08-04 2022-07-08 保定加合精细化工有限公司 一种双萜烯类畜禽用抗生素的制备方法
KR20200141035A (ko) 2018-03-14 2020-12-17 포천 파마슈티컬즈, 엘티디. TRK 키나제 억제제로서의 치환된 (2-아자비사이클로 [3.1.0] 헥산-2-일) 피라졸로 [1, 5-a] 피리미딘 및 이미다조 [1, 2-b] 피리다진 화합물
US11485707B2 (en) 2018-03-23 2022-11-01 Fochon Pharmaceuticals, Ltd. Deuterated compounds as rock inhibitors
CN115197169B (zh) * 2018-11-02 2023-07-11 华南农业大学 一种以2-氨基苯巯醇为连接基团截短侧耳素衍生物制备方法和用途
CN110372615B (zh) * 2019-07-08 2023-02-03 华南农业大学 一种具有2-氨基苯硫醇和1,2,3-三氮唑侧链的截短侧耳素衍生物及制备与应用
CN111170911A (zh) * 2019-09-29 2020-05-19 安帝康（无锡）生物科技有限公司 用于治疗细菌感染性疾病的截短侧耳素类化合物
CN110818648B (zh) * 2019-12-05 2021-03-16 华南农业大学 一种具有三氮唑侧链的截短侧耳素衍生物及其制备方法和应用
CN113666883B (zh) * 2021-07-23 2023-06-16 华南理工大学 一种合成4-乙烯基异噁唑衍生物的方法
CN114940671A (zh) * 2022-05-10 2022-08-26 华南农业大学 一种具有4-氨基苯硫醇侧链的截短侧耳素衍生物及其制备方法和应用
CN115850137B (zh) * 2022-11-12 2024-04-12 中国农业科学院兰州畜牧与兽药研究所 一种截短侧耳素衍生化合物及其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789629A (fr) * 1971-10-05 1973-04-03 Sandoz Sa Nouveaux derives de la pleuromutiline, leur preparation et leurapplication en therapeutique
US4107164A (en) 1971-10-05 1978-08-15 Sandoz Ltd. Certain pleuromulilin ester derivatives
JPS54160358A (en) * 1978-06-06 1979-12-19 Sandoz Ag Improvement for organic compound
ZA80175B (en) * 1979-01-12 1981-08-26 Sandoz Ltd New pleuromutilin derivatives, their production and use
DE2966635D1 (en) * 1979-01-12 1984-03-08 Sandoz Ag New pleuromutilin derivatives, their production and pharmaceutical compositions containing them
DE3405632A1 (de) * 1984-02-17 1985-08-22 Sandoz-Patent-GmbH, 7850 Lörrach Neue pleuromutilinderivate, verfahren zu ihrer herstellung und ihre verwendung
EP0153277B1 (de) 1984-02-17 1987-08-26 Sandoz Ag Neue Pleuromutilinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
HU208115B (en) * 1989-10-03 1993-08-30 Biochemie Gmbh New process for producting pleuromutilin derivatives
AT397654B (de) * 1992-05-04 1994-06-27 Biochemie Gmbh Neue pleuromutilinderivate, ihre verwendung und verfahren zu ihrer herstellung
GB9614017D0 (en) * 1996-07-04 1996-09-04 Biochemie Gmbh Organic compounds
UY25225A1 (es) * 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
WO2000027790A1 (en) * 1998-11-11 2000-05-18 Smithkline Beecham P.L.C. Mutilin compounds
PE20020676A1 (es) * 2000-09-13 2002-08-27 Biochemie Gmbh Compuestos de mutilina como antibacterianos

Also Published As

Publication number Publication date
EP1666466B1 (en) 2010-12-01
HK1047087B (en) 2006-12-22
CA2380980A1 (en) 2001-02-08
CN1364158A (zh) 2002-08-14
EP1198454A1 (en) 2002-04-24
DK1198454T3 (da) 2006-06-12
WO2001009095A1 (en) 2001-02-08
CN1636976A (zh) 2005-07-13
ECSP003591A (es) 2002-02-25
EP1666466A2 (en) 2006-06-07
IL147072A0 (en) 2002-08-14
EP1198454B1 (en) 2006-03-08
DE60026540D1 (de) 2006-05-04
JP2011016834A (ja) 2011-01-27
HUP0202071A2 (en) 2002-10-28
JP4711580B2 (ja) 2011-06-29
DE60045321D1 (de) 2011-01-13
BRPI0017527B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2021-05-25
PT1198454E (pt) 2006-07-31
SI1198454T1 (sl) 2006-08-31
NO20020383L (no) 2002-01-24
MY133731A (en) 2007-11-30
ZA200200695B (en) 2003-05-28
HK1047087A1 (en) 2003-02-07
SK1272002A3 (en) 2002-07-02
AU6832600A (en) 2001-02-19
GB9918037D0 (en) 1999-09-29
PL205609B1 (pl) 2010-05-31
ES2357443T3 (es) 2011-04-26
MXPA02001091A (es) 2002-10-31
NZ516711A (en) 2003-07-25
TWI281468B (en) 2007-05-21
BRPI0017527B1 (pt) 2017-08-29
HK1090636A1 (en) 2006-12-29
CA2380980C (en) 2009-04-14
KR100878074B1 (ko) 2009-01-13
TR200103764T2 (tr) 2002-06-21
HUP0202071A3 (en) 2003-03-28
NO20020383D0 (no) 2002-01-24
CZ2002345A3 (cs) 2002-05-15
KR20020029908A (ko) 2002-04-20
US7534814B2 (en) 2009-05-19
DE60026540T2 (de) 2007-01-18
PE20010544A1 (es) 2001-05-15
KR20070087245A (ko) 2007-08-27
US6784193B1 (en) 2004-08-31
BR0012880A (pt) 2002-04-09
HU229483B1 (en) 2014-01-28
JP2003506354A (ja) 2003-02-18
RU2276135C2 (ru) 2006-05-10
ATE319686T1 (de) 2006-03-15
IL147072A (en) 2007-09-20
EP1666466A3 (en) 2007-09-26
AU757799B2 (en) 2003-03-06
PL352940A1 (en) 2003-09-22
AR024964A1 (es) 2002-10-30
JP5485838B2 (ja) 2014-05-07
CO5180568A1 (es) 2002-07-30
CN1182116C (zh) 2004-12-29
KR100878075B1 (ko) 2009-01-13
ES2259610T3 (es) 2006-10-16
US20040235910A1 (en) 2004-11-25
NO322562B1 (no) 2006-10-23

Similar Documents

Publication Publication Date Title
ATE490240T1 (de) Mutilinderivate und deren verwendung als antimikrobielle agenzien
DE60034713D1 (de) Chinolyl-propyl-piperidinderivate und deren Verwendung als antimikrobielle Wirkstoffe
DE60133897D1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
ATE462691T1 (de) Trifluormethylpyrrolcarbonsäureamide und trifluormethylpyrrolthiocarbonsäureamide als fungizide
ATE342258T1 (de) N-aryl-2-oxazolidinon-5-carbonsäureamide und deren derivate und deren verwendung als antibakterielle mittel
DE59803292D1 (de) Triazolverbindungen und deren verwendung als dopamin-d 3-liganden
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE60015089D1 (de) 3-phenylpyridinderivative und deren verwendung als nk-1 rezeptorantagonisten
DE60025147D1 (de) Kosmetische Zusammensetzung und Verwendungen
EE05350B1 (et) Antiproliferatiivsete vahenditena kasutatavad bensoimidasooli derivaadid
EE200200251A (et) Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
DE50112669D1 (de) Acridin-derivate und deren verwendung als arzneimittel
DE122007000076I2 (de) Pleuromutilin-derivate als antimikrobielles wirkungsmittel
DE50111690D1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
ATE260033T1 (de) Biozide zusammensetzung und deren verwendung
ATE266374T1 (de) Kosmetische tensid-präparate und deren verwendung
DE60022828D1 (de) Kosmetikeinheit und deren Zusammensetzung
DE60021507D1 (de) Uracilverbindungen und deren Verwendung
ATE261959T1 (de) Substituierte phenyl-piperazin-derivate, deren herstellung und verwendung
ATE283844T1 (de) Pyrimidinverbindungen und deren verwendung als pestizide
DE50002417D1 (de) 3-Amino-3-arylpropan-1-ol-Derivate, deren Herstellung und Verwendung
DE50206476D1 (de) Cyanoanthranylamid-derivate und deren verwendung als arzneimittel
DE60005514D1 (de) Dormanz-brechende zusammenstezung und deren verwendung
DE60013191D1 (de) Tensidzusammensetzung und deren Verwendung
DE60311277D1 (de) Benzotriazabicyclische derivate und deren verwendung als beta-lactamaseinhibitoren und antibakterielle mittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties